Experience of using Janus kinase inhibitors in COVID-19 Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment Year: 2021
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020
Tyrosine Kinase Transmembrane Receptor alterations in NSCLC Source: ERS Research Seminar Year: 2015
In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
p38 MAPK inhibitors in COPD Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012
LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia: role of p38 MAP kinase Source: Eur Respir J 2001; 18: Suppl. 33, 73s Year: 2001
Role of p38 mitogen-activated protein kinase in trauma/hemorrhage and subsequent peumococcal pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011
Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Inhibition of phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase prevents malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010
Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
Tyrosine kinase inhibitors beyond progression: never, intercalating or forever? Source: International Congress 2015 – Non-small cell lung cancer (NSCLC): sequence, timing, and modality of multi-line therapies Year: 2015
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017
Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis Source: ERS Lung Science Conference 2020 Year: 2020
Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013